Fibrinolytic Enzymes for Thrombolytic Therapy.

Fibrinolytic Enzymes for Thrombolytic Therapy. Adv Exp Med Biol. 2019;1148:345-381 Authors: Kumar SS, Sabu A Abstract Cardiovascular diseases are a group of disorders consisting importantly of coronary heart disease, peripheral arterial disease, cerebrovascular disease, rheumatic heart disease, congenital heart disease, deep vein thrombosis and pulmonary embolism. Severe cardiovascular disease conditions lead to acute myocardial infarction and stroke. One of the reasons for this is formation of blood clots inside the vessel. Anticoagulants and antiplatelet drugs are used for managing cardiovascular diseases for a long time. However, they were unable to dissolve an existing thrombus. Fibrinolytic enzymes have become more substantial for treating cardiovascular diseases since they could lyse the fibrin clot within the blood vessel. Inability of plasma fibrinolytic system demands better thrombolytic drugs. Major thrombolytic enzymes belonging to plasminogen activators and plasmin like enzymes. Currently used fibrinolytic enzymes and their limitations are revisited in the present chapter. Reported enzymes from various sources with potential to be used as cardiovascular therapeutic is also discussed here. PMID: 31482506 [PubMed - in process]
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research

Related Links:

Publication date: Available online 10 July 2020Source: Clinica Chimica ActaAuthor(s): Elizabeth Fragopoulou, Smaragdi Antonopoulou
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
CONCLUSION: The preventive strategy is fundamental, since the therapy is complex with poorly validated effectiveness. PMID: 32645129 [PubMed - as supplied by publisher]
Source: Jornal Brasileiro de Nefrologia - Category: Urology & Nephrology Tags: J Bras Nefrol Source Type: research
CONCLUSIONS: Extracting from the group of genes related to coronary atherosclerosis and cardiac failure: MMP-9, TGF-β1 and TIMP-1 differentiating patients with heart failure on the basis of myocardial ischemia in varying degrees of severity from healthy people may indicate their significant contribution to disease development. Also increased expression of the metalloproteinase gene 9 (MMP-9) with a simultaneous decrease in the expression of its tissue inhibitor 1 (TIMP-1) in the studied group of patients with ischemic heart failure differing in left ventricular ejection fraction (LVEF) makes them the markers of progre...
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
Authors: Buono A, Ielasi A, Colombo A Abstract Bioresorbable scaffolds (BRS) have been introduced in the last decade in percutaneous coronary interventions. Despite several advantages being postulated, the negative results from the mid-term follow-up of the Absorb trials have tempered enthusiasm for these innovative devices. The Absorb scaffold was associated with higher rates of target-lesion failure and scaffold thrombosis when compared to current metallic stents, and for this reason was withdrawn from the market. This failure has to be considered multifactorial, involving technical and technological aspects. Con...
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
Authors: Stepien K, Furczynska P, Zalewska M, Nowak K, Wlodarczyk A, Owsianka I, Skorek P, Zalewski J, Nessler J Abstract BACKGROUND: Recently heart failure (HF) has been found to be a new dementia risk factor, nevertheless their relations in patients following HF decompensation remain unknown. We sought to investigate whether a screening diagnosis for dementia (SDD) in this high-risk population may predict unfavorable long-term clinical outcomes. METHODS: 142 patients following HF decompensation requiring hospitalization were enrolled. Within a median time of 55 months all patients were screened for dementia w...
Source: Minerva Cardioangiologica - Category: Cardiology Tags: Minerva Cardioangiol Source Type: research
We describe a young man with antiphospholipid syndrome, who developed overt pulmonary thromboembolism due to an isolated thrombus in the left renal vein. Complicating antiphospholipid syndrome might trigger acute pulmonary thromboembolism (APTE) in patients with NCS. To the best of our knowledge, this is the first report of APTE arising due to isolated left renal vein thrombosis in patients with NCS. PMID: 32641637 [PubMed - as supplied by publisher]
Source: International Heart Journal - Category: Cardiology Tags: Int Heart J Source Type: research
Conclusions: CaD did not consistently modify the effect of CEE therapy or CEE + MPA therapy on CVD events. However, the increased risk of stroke due to CEE therapy appears to be mitigated by CaD supplementation. In contrast, CaD supplementation did not influence the risk of stroke due to CEE + MPA.
Source: Menopause - Category: OBGYN Tags: Original Articles Source Type: research
Conclusions: Embolism associated with asymptomatic carotid stenosis shows circadian variation with highest rates 4–6 h before midday. This corresponds with peak circadian incidence of stroke and other vascular complications. These and ASED Study results show that monitoring frequency, duration, and time of day are important in ES detection. Introduction Transcranial Doppler (TCD) detected microembolism in the ipsilateral middle cerebral artery (MCA) may help stratify the risk of stroke and other arterial disease complications in persons with advanced (≥60%) asymptomatic carotid stenosis. If so, this techniqu...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
CONCLUSION: It is concluded that nutraceuticals possess enormous health benefits and their interventions can be highly beneficial in the prevention/reduction of CVDs and related disorders such as atherosclerosis, hypertension, heart attack and stroke. The findings of this review provide an update on the emerging uses of nutraceuticals, functional foods, and herbal remedies in humans. Nevertheless, large-scale randomized, placebo-controlled, double-blind clinical trials are needed to confirm the health benefit claims about nutraceuticals and herbal products to establish their long-term safety and to resolve the controversy ...
Source: Recent Patents on Inflammation and Allergy Drug Discovery - Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research
Conclusion Cyclone, flood and storm related disasters impact on treatment management and overall care for people with NCDs. This results in an increased risk of exacerbation of illness or even death. The interruption may be caused by a range of factors, such as damaged transport routes, reduced health services, loss of power and evacuations. The health impact varies according to the NCD. For people with chronic respiratory diseases, a disaster increases the risk of acute exacerbation. Meanwhile, for people with cancer, cardiovascular diseases and diabetes there is an increased risk of their illness exacerbating, which can ...
Source: PLOS Currents Disasters - Category: Global & Universal Authors: Source Type: research
More News: Biology | Cardiology | Cardiovascular | Coronary Heart Disease | Heart | Heart Attack | Heart Disease | Pulmonary Thromboembolism | Research | Rheumatology | Stroke | Thrombolytic Therapy | Thrombosis